<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>jmedicalcasereports</PublisherName>
      <JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
      <PISSN>I</PISSN>
      <EISSN>S</EISSN>
      <Volume-Issue>Volume 6; Issue 5</Volume-Issue>
      <PartNumber/>
      <IssueTopic>Multidisciplinary</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season>(Sep-Oct, 2025)</Season>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>-0001</Year>
        <Month>11</Month>
        <Day>30</Day>
      </PubDate>
      <ArticleType>Medical Case Reports</ArticleType>
      <ArticleTitle>ECCT Modulates the Therapeutic Landscape for Advanced Lung Adenocarcinoma: A Case Series Demonstrating Efficacy Across EGFR-Mutant and Wild-Type Subtypes</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>1</FirstPage>
      <LastPage>15</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Shinichiro</FirstName>
          <LastName>Akiyama</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>N</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Warsito P.</FirstName>
          <LastName>Taruno</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Edi</FirstName>
          <LastName>Sukur</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Ahmad Novian Rahman</FirstName>
          <LastName>Hakim</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Wamid</FirstName>
          <LastName>Antaboga</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Dessy</FirstName>
          <LastName>Arianty</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
        </Author>
      </AuthorList>
      <DOI/>
      <Abstract>Background: Lung cancer remains a leading cause of cancer-related mortality worldwide. Electro-Capacitive Cancer Therapy (ECCT), a non-invasive treatment utilizing alternating electric fields, has emerged as a promising adjunctive modality by selectively disrupting cancer cell mitosis. This study presents a case series evaluating the clinical outcomes of ECCT as an additive therapy for patients with advanced lung adenocarcinoma. Methods: Six patients with clinical stage IIIA to IVA pulmonary adenocarcinoma (two EGFR wild-type, four EGFR-mutant) were treated with ECCT concurrently with standard therapeutic modalities, including chemotherapy, radiotherapy, immunotherapy, or tyrosine kinase inhibitors (TKIs). ECCT was administered at a frequency of 100–150 kHz and a voltage of 20–30 Vpp, typically for 30 minutes to 4 hours daily, five days a week. Treatment response was evaluated through serial imaging (CT and PET-CT). Safety Monitoring and Adverse Event Assessment: All patients were monitored closely for adverse events (AEs) throughout the treatment period, following a prespecified safety monitoring protocol. All adverse events were prospectively documented and graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Special attention was paid to local skin reactions (dermatitis, erythema, or pain) occurring at the ECCT electrode application sites. Results: Five patients achieved a partial response (PR), and one maintained stable disease (SD), with significant tumor regression observed across all cases. The treatment was exceptionally well-tolerated, with no severe adverse events reported. Clinical improvements were observed irrespective of the patients__ampersandsign#39; EGFR mutation status. Conclusion: This case series suggests that ECCT is a safe and effective adjunctive therapy for stage IV lung adenocarcinoma, significantly enhancing the efficacy of standard treatments across different molecular subtypes. These promising real-world results align with emerging evidence from larger trials and preclinical studies on electric field-based therapies. These findings warrant further investigation in larger, prospective clinical trials to establish ECCT__ampersandsign#39;s definitive role in precision oncology frameworks.</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>Lung Adenocarcinoma,Electro-Capacitive Cancer Therapy,ECCT,EGFR</Keywords>
      <URLs>
        <Abstract>https://www.jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=16007&amp;title=ECCT Modulates the Therapeutic Landscape for Advanced Lung Adenocarcinoma: A Case Series Demonstrating Efficacy Across EGFR-Mutant and Wild-Type Subtypes</Abstract>
      </URLs>
      <References>
        <ReferencesarticleTitle>References</ReferencesarticleTitle>
        <ReferencesfirstPage>16</ReferencesfirstPage>
        <ReferenceslastPage>19</ReferenceslastPage>
        <References>Alamsyah F, Ajrina IN, Dewi FN, Iskandriati D, Prabandari SA, Taruno WP. Antiproliferative effect of electric fields on breast tumor cells in vitro and in vivo. Indonesian Journal of cancer chemoprevention. 2015; 6: 71-7.&#13;
&#13;
Alamsyah F, Firdausi N, Nugraheni SED, Fadhlurrahman AG, Nurhidayat L, Pratiwi R, Taruno WP. Effects of non-contact electric fields on the kidneys and livers of tumour-bearing rats. F1000Res 2025; 12: 117.&#13;
&#13;
Alamsyah F, Pratiwi R, Firdausi N, Irene Mesak Pello J, Evi Dwi Nugraheni S, Ghitha Fadhlurrahman A, Nurhidayat L, Purwo Taruno W. Cytotoxic T cells response with decreased CD4/CD8 ratio during mammary tumors inhibition in rats induced by non-contact electric fields. F1000Res 2021; 10: 35.&#13;
&#13;
Bhutia YD, Babu E, Ramachandran S, Yang S, Thangaraju M, Ganapathy V. SLC transporters as a novel class of tumour suppressors: identity, function and molecular mechanisms. Biochem J 2016; 473: 1113-1124.&#13;
&#13;
Boedtkjer E, Pedersen SF. The Acidic Tumor Microenvironment as a Driver of Cancer. Annu Rev Physiol 2020; 82: 103-126.&#13;
&#13;
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229-263.&#13;
&#13;
Clara JA, Monge C, Yang Y, Takebe N. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. Nat Rev Clin Oncol 2020; 17: 204-232.&#13;
&#13;
Gurney JK, Millar E, Dunn A, Pirie R, Mako M, Manderson J, Hardie C, Jackson CGCA, North R, Ruka M, Scott N, Sarfati D. The impact of the COVID-19 pandemic on cancer diagnosis and service access in New Zealand-a country pursuing COVID-19 elimination. Lancet Reg Health West Pac 2021; 10: 100127.&#13;
&#13;
Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y. Disruption of cancer cell replication by alternating electric fields. Cancer Res 2004; 64: 3288-3295.&#13;
&#13;
Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y. Disruption of cancer cell replication by alternating electric fields. Cancer Res 2004; 64: 3288-3295.&#13;
&#13;
Medema JP, Vermeulen L. Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. Nature 2011; 474: 318-326.&#13;
&#13;
Patt D, Gordan L, Diaz M, Okon T, Grady L, Harmison M, Markward N, Sullivan M, Peng J, Zhou A. Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors. JCO Clin Cancer Inform 2020; 4: 1059-1071.&#13;
&#13;
Pratiwi R, Antara NY, Fadliansyah LG, Ardiansyah SA, Nurhidayat L, Sholikhah EN, Sunarti S, Widyarini S, Fadhlurrahman AG, Fatmasari H, Tunjung WAS, Haryana SM, Alamsyah F, Taruno WP. CCL2 and IL18 expressions may associate with the anti-proliferative effect of noncontact electro capacitive cancer therapy in vivo. F1000Res 2019; 8: 1770.&#13;
&#13;
Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA 2017; 318: 2306-2316.&#13;
&#13;
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-249.&#13;
&#13;
Zhang D, Tang Z, Huang H, Zhou G, Cui C, Weng Y, Liu W, Kim S, Lee S, Perez-Neut M, Ding J, Czyz D, Hu R, Ye Z, He M, Zheng YG, Shuman HA, Dai L, Ren B, Roeder RG, Becker L, Zhao Y. Metabolic regulation of gene expression by histone lactylation. Nature 2019; 574: 575-580.</References>
      </References>
    </Journal>
  </Article>
</ArticleSet>